Report sparks Alvogen sale rumors

The US operations of New Jersey-based generics drugmaker Alvogen could be sold by its private equity owners to Shanghai Pharmaceutical Holding, according to a report from the news service Bloomberg.

The  report claims that controlling shareholders including CVC Capital Partners, who only bought into Alvogen in 2015, have held talks with the Chinese drugmaker about the deal that would see Alvogen hang onto its operations in smaller Asian and European markets.

Alvogen could be valued at about $4 billion, according to the article.